Head to Head Analysis: BioTelemetry (BEAT) vs. Cannabis Science (CBIS)

BioTelemetry (NASDAQ: BEAT) and Cannabis Science (OTCMKTS:CBIS) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their profitability, earnings, risk, valuation, institutional ownership, dividends and analyst recommendations.

Analyst Ratings

This is a breakdown of recent recommendations and price targets for BioTelemetry and Cannabis Science, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
BioTelemetry 1 0 7 0 2.75
Cannabis Science 0 0 0 0 N/A

BioTelemetry presently has a consensus target price of $43.50, indicating a potential upside of 56.76%. Given BioTelemetry’s higher possible upside, equities research analysts plainly believe BioTelemetry is more favorable than Cannabis Science.

Insider and Institutional Ownership

82.4% of BioTelemetry shares are held by institutional investors. 9.6% of BioTelemetry shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Earnings & Valuation

This table compares BioTelemetry and Cannabis Science’s revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
BioTelemetry $208.33 million 4.32 $53.43 million $1.29 21.51
Cannabis Science N/A N/A N/A N/A N/A

BioTelemetry has higher revenue and earnings than Cannabis Science.

Volatility & Risk

BioTelemetry has a beta of 0.53, indicating that its share price is 47% less volatile than the S&P 500. Comparatively, Cannabis Science has a beta of -3.62, indicating that its share price is 462% less volatile than the S&P 500.

Profitability

This table compares BioTelemetry and Cannabis Science’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
BioTelemetry 16.10% 13.66% 8.44%
Cannabis Science -953,196.00% N/A -380.46%

Summary

BioTelemetry beats Cannabis Science on 9 of the 9 factors compared between the two stocks.

About BioTelemetry

BioTelemetry, Inc. (BioTelemetry), formerly CardioNet, Inc., provides cardiac monitoring services, cardiac monitoring device manufacturing, and centralized cardiac core laboratory services. The Company operates in three segments: patient services, product and research services. The patient services business segment’s principal focus is on the diagnosis and monitoring of cardiac arrhythmias or heart rhythm disorders, through its core Mobile Cardiac Outpatient Telemetry(MCOT), event and Holter services in a healthcare setting. The product business segment focuses on the development, manufacturing, testing and marketing of medical devices to medical companies, clinics and hospitals. The Company’s research services focuses on providing cardiac safety monitoring services for drug and medical treatment trials in a research environment. In August 2012, the Company completed the acquisition of Cardiocore Lab, Inc. (Cardiocore).

About Cannabis Science

Cannabis Science, Inc. is engaged in medical marijuana research and development. The Company works on phytocannabinoid science targeting critical illnesses, and adheres to scientific methodologies to develop, produce and commercialize phytocannabinoid-based pharmaceutical products. The Company is involved in the creation of cannabis-based medicines, both with and without psychoactive properties, to treat disease and the symptoms of disease, as well as for general health maintenance. The Company focuses on the development of governmentally approved pharmaceuticals, including CS-TATI1, CS-S/BCC-1 and neurological therapy under study or development. The Company’s subsidiaries include Cannabis Science BV and Cannabis Science International Holding BV.

Receive News & Ratings for BioTelemetry Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioTelemetry and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply